Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT). Beernink J, Oosterwijk MM, Van Boven JF, Heerspink H, Bakker SJ, Navis G, Nijboer RM, Gant CM, Haverkate H, Kruik-Kollöffel WJ, Laverman GD. Front Pharmacol. 2022;13:888110.

Non‑cardiovascular medication and readmission for heart failure: an observational cohort study. Kruik‑Kollöffel WJ, Vallejo‑Yagüe E, Movig KLL, Linssen GCM, Heintjes EM, Van der Palen J. Int J Clin Pharm 2022;44:762-768.

Veranderingen in antidepressivaspiegels na een one-anastomosis gastric bypass: een pilotstudie. Warmerdam EC, Damhof MA, Kruik-Kollöffel WJ. Nederlands Platform voor Farmaceutisch Onderzoek 2022;7:a1754.

The Dutch Working Party on Antibiotic Policy (SWAB) recommendations for the diagnosis and management of febrile neutropenia in patients with cancer. De la Court JR, Bruns AHW, Roukens AHE, Baas IO, Van Steeg K, Toren-Wielema ML, Tersmette M, Blijlevens NMA, Huis In 't Veld RAG, Wolfs TFW, Tissing WJE, Kyuchukova Y, Heijmans J. Infect Dis Ther. 2022;11(6):2063-2098. doi: 10.1007/s40121-022-00700-1.

Citraatbuffer verlengt de houdbaarheid van flucloxacillineoplossing voor continue intraveneuze thuistoediening. Warnders FJ, Selles S, Hondebrink VW, Henstra MJ. Nederlands Platform voor Farmaceutisch Onderzoek 2022;7:a1752.

Kunstmatige intelligentie helpt apotheker bij complexe beslissing. Mian P, Metzlar K, Hogenhuis F. Pharm Weekbl 2022;157:14-6.

Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial. Schweitzer VA, van Heijl I, Boersma WG, Rozemeijer W, Verduin K, Grootenboers MJ, Sankatsing SUC, van der Bij AK, de Bruijn W, Ammerlaan HSM, Overdevest I, Roorda-van der Vegt JMM, Engel-Dettmers EM, Ayuketah-Ekokobe FE, Haeseker MB, Dorigo-Zetsma JW, van der Linden PD, Boel CHE, Oosterheert JJ, van Werkhoven CH, Bonten MJM. Lancet Infect Dis. 2022;22:274-83.

Patient and health care provider perspectives on potential preventability of hospital admission for acute exacerbation of chronic obstructive pulmonary disease: a qualitative study. Leenders A, Sportel E, Poppink E, Van Beurden W, Van der Valk P, Brusse-Keizer M. Patient Prefer Adherence. 2022;16:3207-3220. doi: 10.2147/PPA.S380862

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Touw DJ, van der Weide J, van Westrhenen R, Deneer VHM, Guchelaar HJ, Swen JJ. Eur J Hum Genet. 2022 Nov 28. doi: 10.1038/s41431-022-01243-2. Online ahead of print. PMID: 36443464 Review.

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. Eur J Cancer. 2022 Feb;162:148-157. doi: 0.1016/j.ejca.2021.12.009. Epub 2022 Jan 5. PMID: 34998046

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism? Hulshof EC, de With M, Creemers GJ, Guchelaar HJ, Mathijssen RH, Gelderblom H, Deenen MJ. Eur J Cancer. 2022 Sep;172:231-233. doi: 10.1016/j.ejca.2022.05.045. Epub 2022 Jul 3. PMID: 35793611 No abstract available.

Publicaties

Publicaties

Publicaties 2024

Publicaties 2023

Publicaties 2022